Group 1 - The company announced the appointment of Dr. Chen Pao-Jian as an independent non-executive director and a member of the audit committee, effective from November 11, 2025 [1] - The board also appointed Professor Wang Qinmei as a non-executive director, effective from November 11, 2025 [1]

Group 1 - The company announced the appointment of Chen Pojian as an independent non-executive director and a member of the audit committee, effective from November 11, 2025 [1] - Professor Wang Qinmei has been appointed as a non-executive director by the board, also effective from November 11, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 解除委聘特別委員會法證顧問； 重組特別委員會； 及 重組獨立特別委員會 特別委員會及獨立特別委員會 特別調查委員會（「特別委員會」）乃由兩名獨立非執行董事鄭宇凌女士（「鄭女士」） 及王燦先生（「王先生」）組成，其成立旨在調查多項指控（「企業管治指控」），當 中包括本公司日期為二零二五年五月三十日的公告中披露的「其他指控」以及其他 涉及若干董事及前任董事的指控。於二零二五年三月二十六日，特別委員會委任 PricewaterhouseCoopers Consulting Hong Kong Limited（「PwC Consulting」）為特 別委員會法證顧問。 本公司亦於二零二五年五月十三日及二零二五年五月三十日公佈，其已接獲有關 其首次公開發售 ...

CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 董事名單及其角色與職能 執行董事 清晰醫療集團控股有限公司董事（「董事」）會（「董事會」）成員名單載列如下： 蔣波先生 （行政總裁） 許勇先生 （聯席行政總裁） 非執行董事 董事會設有三個董事委員會。董事委員會的組成載列如下： 審核委員會 王燦先生 （主席） 鄭宇凌女士 陳剖建博士 1 薪酬委員會 胡定旭先生 （主席） 陳家榮先生 王勤美教授 獨立非執行董事 鄭宇凌女士 王燦先生 慈瑩女士 陳剖建博士 王燦先生 （主席） 慈瑩女士 陳家榮先生 提名委員會 胡定旭先生 （主席） 王燦先生 慈瑩女士 香港，二零二五年十一月十一日 2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） (1)委任獨立非執行董事及審核委員會成員； (2)委任非執行董事； (3)授權代表變更；及 (4)重新遵守上市規則 1 陳博士為高級經濟師，擁有中南財經政法大學經濟學博士學位。彼於一九八六年 獲得中央財經大學學士學位，一九九二年獲得中南財經政法大學碩士學位。 一九八八年，陳博士作為創始團隊成員加入中國平安保險（集團）股份有限公司， 擔任江蘇分公司再保險部總經理。彼於一九九四年創立天安保險股份有限公司及 於二零零一年創立恒康天安人壽保險有限公司。於一九九四年十月至二零一零年 三月，彼擔任天安保險股份有限公司首席執行官兼董事長。二零一二年，陳博士 創立中國紅瑞資本管理集團有限公司並擔任首席執行官。二零一六年，陳博士主 導成立瑞華健康保險股份有限公司， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清晰醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 一名前董事破產及 涉及該名前董事及本公司的法律訴訟的潛在影響 清晰醫療集團控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此提述本 公司日期為二零二五年八月一日及二零二五年九月十六日的公告，內容有關董事 會因謝偉業暫停還款或與債權人達成債務和解協議而於二零二五年八月一日撤銷 謝偉業執行董事職務。謝偉業因此成為前董事。 謝偉業的破產令 應本公司一家附屬公司前醫生提出的破產呈請，法庭於二零二五年十一月三日作 出針對謝偉業的破產令，並於該日生效。本公司已獲其香港法律顧問告知，破產 令的即時法律效力為謝偉業的財產（不論位於何處）均歸屬於香港破產管理署署 長，其擔任謝偉業的臨時受託人。謝偉業的所有債權人可向破產管理署署長提交 債權證明。破產管理 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 清晰醫療集團控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01406 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | 本月底法定/註冊股本總額： HKD 50,000,000 F ...

Core Viewpoint - Clear Medical (01406) has experienced a slight decline in revenue for the first half of the fiscal year 2026, attributed to adverse weather conditions and negative media coverage related to a former director's allegations [1] Group 1: Shareholder Activity - On October 24, shareholders of Clear Medical transferred shares from Hongzhi Securities to Huafu Jianye Securities, with a market value of approximately HKD 22.5 million, representing 11.82% of the total shares [1] Group 2: Financial Performance - For the first half of the fiscal year 2026, Clear Medical reported revenues of approximately HKD 85 million, reflecting a slight decrease of less than 3% compared to the same period last year [1] - The company's operations were significantly impacted by extreme weather, leading to the closure or severe disruption of its Hong Kong clinics for eight days between July and September [1] Group 3: Business Challenges - Negative media coverage stemming from allegations against a former director may adversely affect the company's business in the coming months [1]

Group 1 - The core point of the article highlights that Clear Medical (01406) has experienced a slight decline in revenue for the fiscal half-year ending in 2026, reporting approximately HKD 85 million, which is a decrease of less than 3% compared to the same period last year [1] - The company faced operational disruptions due to extreme weather conditions, resulting in its Hong Kong clinics being closed or severely interrupted for eight days between July and September [1] - Negative media coverage stemming from allegations against a former director may adversely affect the company's business in recent months [1] Group 2 - On October 24, shareholders transferred shares from Hongzhi Securities to Huafu Jianye Securities, with a market value of HKD 22.5026 million, representing 11.82% of the total shares [1]

Core Viewpoint - Clear Medical (01406.HK) reported a slight decline in revenue for the first half of the fiscal year ending September 30, 2025, due to adverse weather conditions and negative media coverage affecting business operations [1] Financial Performance - The group recorded revenue of approximately HKD 85 million, representing a decrease of less than 3% compared to the same period last year [1] Operational Challenges - The Hong Kong clinics experienced eight days of closure or significant disruption from July to September due to extreme weather conditions [1] - Negative media coverage stemming from allegations against a former director has adversely impacted the group's business in recent months [1] Strategic Developments - The company has strengthened its position in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1] Management Focus - Ongoing allegations have hindered the execution of key strategic plans and affected business operations [1] - The group is committed to efficiently completing the relevant investigations to stabilize operations and allow management to refocus on long-term strategic priorities [1] Stock Trading Status - The company's shares have been suspended from trading on the Hong Kong Stock Exchange since April 15, 2025, and will remain suspended until further notice [1]